Transgenic Nonhuman Animal (e.g., Mollusks, Etc.) Patents (Class 800/13)
-
Publication number: 20120090043Abstract: The invention concerns an isolated complex comprising an HIV or HTLV protein and a human protein. Corresponding nucleic acids, vectors, host cells, host organisms, compositions, kits, medical uses, diagnostic uses, and methods of screening agents are also contemplated. Disclosed are 212 interactions between 19 retroviral proteins and 131 human proteins.Type: ApplicationFiled: June 30, 2010Publication date: April 12, 2012Applicant: UNIVERSITE DE LIEGEInventors: Jean-Claude Twizere, Nicolas Simonis
-
Publication number: 20120084873Abstract: The present invention relates generally to the field of sex determination of animals. Provided are methods and agents to manipulate sex determination, particularly in avian animals such as chickens, through a male chromosome-linked testis (sex) regulatory gene. Expression or activity of the DMRT1 gene or protein is modulated to produce animals with displaying a phenotype sex that differs from their genotype.Type: ApplicationFiled: February 8, 2010Publication date: April 5, 2012Inventors: Andrew Sinclair, Craig Smith, Timothy James Doran, Robert John Moore, John William Lowenthal
-
Publication number: 20120082987Abstract: The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.Type: ApplicationFiled: March 24, 2011Publication date: April 5, 2012Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Maria Sasgary, Maria Schuster, Hans-Peter Schwarz, Birgit Reipert, Gerhard Antoine, Hartmut Ehrlich
-
Patent number: 8148600Abstract: Immunocompromised rodents that have been modified to express a fluorescent protein in substantially all tissues are described. These rodents are useful as models for gene expression, tumor progression and angiogenesis. Also provided are model systems where heterologous tissues fluorescing in a first color are transplanted into hosts that have been modified to fluoresce in substantially all tissues with a second color.Type: GrantFiled: February 9, 2004Date of Patent: April 3, 2012Assignee: Anticancer, Inc.Inventors: Meng Yang, Eligio Reynoso, Mingxu Xu, Ping Jiang
-
Publication number: 20120079613Abstract: The present invention relates to the human homeobox transcription factor Bsx protein, nucleic acids encoding for said protein, vectors and cells comprising the nucleic acids, antibodies directed against Bsx, and methods for identifying compounds binding to Bsx, as well as to the use of proteins, nucleic acids, vectors, cells, and interacting compounds for treating obesity and related diseases.Type: ApplicationFiled: April 2, 2007Publication date: March 29, 2012Applicants: Deutsches Institut fur Ernahrungsforschung (DIFE), European Molecular Biology Laboratory (EMBL)Inventors: Mathias Treier, Maria Sakkou, Petra Wiedmer, Matthias Tschoep
-
Publication number: 20120077860Abstract: The invention concerns an adeno-associated viral vector comprising: a U7 type modified snRNA sequence; the native U7 promoter; at least one antisense sequence directed against at least one splice site of at least one exon, the said exon encoding a dispensable domain of dystrophin.Type: ApplicationFiled: August 2, 2005Publication date: March 29, 2012Applicants: GENETHON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Luis Garcia
-
Publication number: 20120073508Abstract: The present invention relates to a nucleic acid molecule encoding an insulin-like factor of the androgenic gland of the freshwater prawn Macrobrachium rosenbergii (M. rosenbergii). The present invention further relates to methods of silencing the expression of the insulin-like factor gene in decapod crustaceans order, particularly in M. rosenbergii, useful for producing male monosex populations.Type: ApplicationFiled: October 19, 2011Publication date: March 29, 2012Applicant: Ben-Gurion University of the Negev Research and Development AuthorityInventors: Amir Sagi, Tomer Ventura
-
Publication number: 20120073005Abstract: The present invention relates to a transgenic animal which intracellularly expresses at least two types of foreign functional RNA and has resistance to a pathogen such as a virus. In the animal carrying multiple types of foreign functional RNA, the proliferation of a pathogen can be more significantly inhibited compared to an animal carrying one type of foreign functional RNA.Type: ApplicationFiled: April 28, 2010Publication date: March 22, 2012Applicant: KANEKA CORPORATIONInventors: Hiroyuki Watanabe, Maki Masutani, Kenji Kyogoku
-
Publication number: 20120070444Abstract: A transgenic non-human animal for overexpressing isoQC, comprising cells containing a DNA transgene encoding human isoQC, characterized in that said human isoQC comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% sequence identity to the amino acid sequence of SEQ ID NO: 1 or a fragment or derivative of the amino acid sequence of SEQ ID NO: 1. Additionally disclosed is a method of screening for biologically active agents that inhibit or promote isoQC.Type: ApplicationFiled: September 2, 2011Publication date: March 22, 2012Applicant: PROBIODRUG AGInventors: Sigrid Graubner, Reinhard Sedlmeier, Andreas Becker, Stephan Schilling, Holger Cynis, Hans-Ulrich Demuth
-
Publication number: 20120070456Abstract: The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.Type: ApplicationFiled: December 1, 2010Publication date: March 22, 2012Inventors: Rino Rappuoli, Guido Grandi
-
Publication number: 20120066775Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: October 1, 2010Publication date: March 15, 2012Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Publication number: 20120066782Abstract: The present invention relates to a kit for detection of association of a peripheral cellular membrane binding protein with cellular membranes in living cells and methods thereof. The kit includes a first nucleic acid construct comprising a first nucleic acid molecule encoding a first fusion protein comprising a peripheral cellular membrane binding protein or membrane binding domain thereof operatively coupled to DNA binding and transactivation domains of a naturally occurring or chimeric transcription factor and a first promoter operatively associated with the first nucleic acid molecule. A second nucleic acid construct comprises a second nucleic acid molecule encoding a reporter protein and a second promoter responsive to the DNA binding and transactivation domains of the first fusion protein. The second promoter is operatively associated with the second nucleic acid molecule. Activation of the second promoter results in expression of the reporter protein. Also disclosed is a transgenic non-human animal.Type: ApplicationFiled: August 31, 2011Publication date: March 15, 2012Applicant: NEW YORK UNIVERSITYInventors: Mark R. PHILIPS, Nicole FEHRENBACHER, Joseph WYNNE
-
Publication number: 20120065375Abstract: The present invention relates to a recombinant organism having any one of nucleic acids (i) to (iv) introduced therein: (i) a nucleic acid having a base sequence of SEQ ID NO: 1; (ii) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2; (iii) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (i); (iv) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (i) under stringent conditions.Type: ApplicationFiled: September 7, 2011Publication date: March 15, 2012Applicant: OKAMOTO CORPORATIONInventors: Tianfu ZHAO, Masao NAKAGAKI
-
Publication number: 20120066776Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.Type: ApplicationFiled: August 19, 2011Publication date: March 15, 2012Inventors: William Vainchenker, Valérie Ugo, Chloé James, Jean-Pierre Le Couedic, Nicole Casadevall
-
Patent number: 8134044Abstract: A transgenic animal such as a transgenic snake or other reptile that expresses a heterologous expression product is described, along with methods of making the same. In general, the animal comprises cells containing a sequence encoding the heterologous expression product. The sequence encoding the heterologous expression product is integrated into the genome of the animal (e.g., in some or all cells thereof, and in some embodiments into germ cells thereof). The sequence encoding the heterologous expression product is, in general, operatively associated with an expression sequence or promoter. The animals are useful for, among other things, testing of repellents, testing of toxicological compounds, as teaching aids, for venom production, etc.Type: GrantFiled: December 18, 2009Date of Patent: March 13, 2012Assignee: North Carolina State UniversityInventors: Paul E. Mozdziak, James N. Petitte
-
Patent number: 8124832Abstract: Provided is a method for producing a cloned dog by enucleating an oocyte of a dog to produce an enucleated oocyte, transferring a somatic cell of the dog into the enucleated oocyte, carrying out electrofusion under optimized conditions to produce a nuclear transfer embryo, and transferring the nuclear transfer embryo into its surrogate mother.Type: GrantFiled: June 13, 2007Date of Patent: February 28, 2012Assignee: Seoul National University Industry FoundationInventors: Byeong Chun Lee, Sung Keun Kang, Dae Yong Kim, Min Kyu Kim, Goo Jang, Hyun Ju Oh, M. Shamim Hossein, Fibrianto Yuda, Hye Jin Kim, So Gun Hong, Jung Eun Park, Joung Joo Kim
-
Patent number: 8124829Abstract: The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence.Type: GrantFiled: October 20, 2010Date of Patent: February 28, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventors: David M. Stern, Ann Marie Schmidt, Shi Du Yan
-
Patent number: 8124830Abstract: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject.Type: GrantFiled: January 28, 2009Date of Patent: February 28, 2012Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron
-
Publication number: 20120047588Abstract: Methods are disclosed in which the expression of a specific gene, or combinations of genes, is controlled spatially and temporally to develop intra- and interspecies chimeras. A transgenic EC/ES/P/iPS cell line is created which conditionally expresses a suicide or compromiser gene configured to compromise all cell lineages except that corresponding to a target tissue/organ. The EC/ES/P/iPS cell line is injected into donor embryos having a specific target gene deficiency or embryos genetically engineered to be complementary compromised in lineages corresponding to the target tissue/organ cell lineages of the EC/ES/P/iPS line. One or more stimuli is provided to the embryo to activate compromiser genes for ablation of non-target tissues/organs of the EC/ES/P/iPS line and target tissues/organs of the host embryo, resulting in a chimeric animal having target tissues/organs derived from the genotype of the transgenic cell line and all remaining tissues/organs derived from the donor embryo.Type: ApplicationFiled: September 1, 2011Publication date: February 23, 2012Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Chongbei Zhao, Andras Nagy, John K. Critser
-
Publication number: 20120047586Abstract: Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.Type: ApplicationFiled: October 23, 2008Publication date: February 23, 2012Applicant: Otsuka Chemical Co., LtdInventors: Takashi Tsuji, Yasuhiro Kajihara, Katsunari Tezuka, Yuri Nambu, Kazuhiro Fukae, Hiroaki Asai
-
Publication number: 20120047585Abstract: The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.Type: ApplicationFiled: August 8, 2008Publication date: February 23, 2012Applicant: Medarex, Inc.Inventors: Daniel K. Rohrer, Nancy Amelia Black, Nils Lonberg
-
Publication number: 20120042400Abstract: Novel polypeptides, designated RTD, which are capable of binding Apo-2 ligand are provided. Compositions including RTD chimeras, nucleic acid encoding RTD, and antibodies to RTD are also provided.Type: ApplicationFiled: November 29, 2010Publication date: February 16, 2012Applicant: GENENTECH, INC.Inventors: Avi J. Ashkenazi, Austin Gurney
-
Publication number: 20120042399Abstract: The present invention relates to immunogenic peptides and their various applications. In particular the invention relates to immunogenic peptides derived from the PASD1 protein and their use in therapeutic, diagnostic and prognostic methods.Type: ApplicationFiled: October 1, 2009Publication date: February 16, 2012Inventors: Karen Pulford, Alison Banham, Amanda Anderson, Kamel Ait-Taho-ar
-
Publication number: 20120030780Abstract: The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are disclosed which demonstrate that constitutive expression of SALL4 increases leukemogenic potential in cells of model animal systems. Moreover, constitutive expression of select isoforms (e.g., SALL4B) in transgenic mice demonstrate that these animals develop myelodysplastic syndrome (MDS)-like signs and symptoms, including subsequent acute myeloid leukemia (AML), which is transplantable. The disclosure also provides methods for identifying and purifying embryonic stem cells, adult stem cells, cancer stem cells, including leukemia stem cells, methods for identifying substances which bind to and/or modulate SALL4, methods for diagnosing MDS in a subject, and methods of treating a subject presenting MDS.Type: ApplicationFiled: August 2, 2010Publication date: February 2, 2012Inventor: Yupo Ma
-
Publication number: 20120030781Abstract: A polynucleotide consisting of the base sequence of SEQ ID NO:2, or a complementary strand thereto, wherein the X is one of the group being defined by the bases A, C or T. A primer and a probe specific for that polynucleotide, wherein the primer and/or probe contains at least 10 consecutive nucleotides, and finally use of the probe for proving parkinsonism inheritance.Type: ApplicationFiled: June 29, 2011Publication date: February 2, 2012Inventors: Jan O. Aasly, Zbigniew K. Wszolek, Matthew J. Farrer
-
Publication number: 20120023600Abstract: Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.Type: ApplicationFiled: January 12, 2007Publication date: January 26, 2012Inventors: Janine Shulok, Feng Cong, Mark Fishman, Seth Ettenberg, Michael Bardroff, Mariel Donzeau, Stefanie Urlinger
-
Publication number: 20120023599Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding cytochrome P450 (CYP) proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence encoding CYP proteins, as well as methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 26, 2012Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Victoria Brown-Kennerly
-
Patent number: 8097248Abstract: The present invention relates to a novel mite composition comprising a population of the phytoseiid predatory mite species Amblyseius swirskii. and a factitious host population, which may be employed for rearing said phytoseiid predatory mite species or for releasing the phytoseiid predatory mite species in a crop. According to further aspects the invention relates to a method for rearing the phytoseiid predatory mite species Amblyseius swirskii, to the use of the mite composition and to a method for biological pest control in a crop, which employ the mite composition.Type: GrantFiled: December 31, 2004Date of Patent: January 17, 2012Assignee: Koppert B.V.Inventors: Karel Jozef Florent Bolckmans, Yvonne Maria van Houten
-
Publication number: 20120011597Abstract: Disclosed is human genomic DNA having the following STR marker profile: Amel D3S1358 VWA FGA D8S1179 D21S11 D18S51 M 15-17 16-17 21-25 12-14 29-32.2 17-18 D5S818 D13S317 D7S820 CSF1PO TPOX TH01 D16S539 11-12 11-12 8-8 10-11 8-8 7-9.3 10-13 And the use thereof as a reference for studying variations in the human genome that may be associated with certain genetic traits or diseases.Type: ApplicationFiled: June 29, 2011Publication date: January 12, 2012Inventor: Charles Timberlake Zeleny
-
Patent number: 8093450Abstract: Nucleic acid compositions encoding non-aggregating chromo/fluoroproteins and mutants thereof, as well as the proteins encoded by the same, are provided. The proteins of interest are polypeptides that are non-aggregating colored and/or fluorescent proteins, where the non-aggregating feature arises from the modulation of residues in the N-terminus of the protein and the chromo and/or fluorescent feature arises from the interaction of two or more residues of the protein. Also provided are fragments of the subject nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications, e.g., that include the subject nucleic acid compositions, are provided.Type: GrantFiled: May 17, 2010Date of Patent: January 10, 2012Assignee: Clontech Laboratories, Inc.Inventors: Sergey Lukyanov, Konstantin Lukyanov, Yuriy Yanushevich, Alexandr Savistky, Arcady Fradkov
-
Publication number: 20120005767Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: June 27, 2011Publication date: January 5, 2012Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
-
Publication number: 20120005768Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.Type: ApplicationFiled: September 6, 2011Publication date: January 5, 2012Applicant: WYETH LLCInventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
-
Publication number: 20110321182Abstract: The present invention is directed to mutations in the DGAT1 gene that produce an advantageous milk, tissue and/or growth rate profile in animals carrying the mutations. The present invention is also directed to methods of identifying animals carrying the mutations in order to facilitate the selection of animals with altered milk, tissue and/or growth rate traits.Type: ApplicationFiled: December 24, 2009Publication date: December 29, 2011Inventors: Klaus Lehnert, Sarah Dianne Berry, Russell Grant Snell, Alastair Kenneth Hugh MacGibbon, Richard Spelman, Alexandra Ankersmit-Udy
-
Publication number: 20110321183Abstract: The present invention relates to methods for ligation. The invention provides novel reagents and methods for ligating an acyl donor compound with an acyl acceptor compound. Provided acyl donor compounds comprise a transamidase recognition sequence that allows ligation with a nucleophilic acyl acceptor in the presence of transamidase. The invention further provides kits comprising acyl donor compounds and optionally comprising other reagents for ligation.Type: ApplicationFiled: February 1, 2010Publication date: December 29, 2011Applicant: Whitehead Institute for Biomedical ResearchInventors: Hidde L. Ploegh, John M. Antos, Maximilian Popp Wei-Lin, Carla Guimaraes
-
Publication number: 20110314565Abstract: The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA hound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis.Type: ApplicationFiled: May 10, 2011Publication date: December 22, 2011Inventors: Nathaniel Heintz, Tito A. Serafini, Andrew W. Shyjan
-
Publication number: 20110314564Abstract: The present invention relates to enzymes which are able to hydrolyse phenylureas, carbamates, and/or organophosphates, as well as polynucleotides encoding these enzymes. The present invention also relates to methods of hydrolysing phenylureas, carbamates, and/or organophosphates.Type: ApplicationFiled: July 8, 2009Publication date: December 22, 2011Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Jeevan L. Khurana, Colin J. Jackson, Colin Scott, Gunjan Pandey, Robyn J. Russell, John G. Oakeshott
-
Patent number: 8076531Abstract: The present invention relates to a transgenic animal, which comprises in its genome a recombinant polynucleotide encoding one or more reporter proteins and a monocyte chemotactic protein-1 (MCP-1) promoter, wherein the one or more reporter proteins are expressed under the control of the MCP-1 promoter. A method for monitoring endogenous expression of MCP-1 in vivo is also provided, which is useful for identifying a regulator of the expression of MCP-1 or an anti-inflammatory agent.Type: GrantFiled: November 25, 2009Date of Patent: December 13, 2011Assignee: National Health Research InstitutesInventor: Kurt Ming-Chao Lin
-
Publication number: 20110296543Abstract: The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs. Polypeptides of the invention can be used in food processing, brewing, bath additives, alcohol production, peptide synthesis, enantioselectivity, hide preparation in the leather industry, waste management and animal degradation, silver recovery in the photographic industry, medical treatment, silk degumming, biofilm degradation, biomass conversion to a biofuel (e.g., a bioethanol, biomethanol, biopropanol or biobutanol, a biodiesel, etc.Type: ApplicationFiled: November 26, 2008Publication date: December 1, 2011Applicants: The University of California, California Institute Technology, Verenium CorporationInventors: Hwai Chang, Eric J. Mathur, Michelle Cayouette, Dan E. Robertson, Philip Hugenholtz, Falk Warnecke, Jared R. Leadbetter, Natalia Ivanova, Peter Luginbuhl, Don Hutchison
-
Publication number: 20110296539Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.Type: ApplicationFiled: August 7, 2009Publication date: December 1, 2011Inventors: Markus Zweckstetter, Pinar Karpinar, Christian Griesinger
-
Publication number: 20110296544Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: May 16, 2011Publication date: December 1, 2011Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Alqun Li, Tao He, Ian McCaffery
-
Publication number: 20110289622Abstract: The invention relates to expression cassettes and vectors which contain constitutive promoters of plants and to the use of these expression cassettes or vectors for transgenic expression of nucleic acid sequences, preferably selection markers, in organisms, preferably in plants. The invention further relates to transgenic plants which have been transformed with the expression cassettes or vectors, to cultures, parts or propagation material derived from these plants, and to the use of these plants for the production of food and animal feedstuffs, seed, pharmaceuticals, or fine chemicals.Type: ApplicationFiled: May 23, 2011Publication date: November 24, 2011Applicant: SunGene GmbH & Co. KGaAInventors: Ute Heim, Helke Hillebrand, Irene Kunze, Karin Herbers, Uwe Sonnewald, Eric Glickmann, Wolfgang Lein, Rüdiger Hell, Ricarda Jost
-
Publication number: 20110289609Abstract: Neurotransmitter biosensors are disclosed, including YbeJ-based glutamate binding biosensors, comprising a neurotransmitter binding domain conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon binding neurotransmitter. Such biosensors are useful for the detection of neurotransmitter concentrations in vivo and in culture.Type: ApplicationFiled: June 25, 2010Publication date: November 24, 2011Inventors: Sakiko Okumoto, Loren L. Looger, Wolf B. Frommer
-
Publication number: 20110289610Abstract: An HCV/GBV-B chimeric virus which maintains the replication function of HCV and is capable of infecting tamarin is disclosed in order to construct an HCV animal model which can be used as a development or evaluation system for therapeutic agents for HCV. The HCV/GBV-B chimeric RNA comprises an RNA of hepatitis C virus and an RNA of GB virus-B, wherein the RNA of hepatitis C virus comprises an RNA encoding leucine at the 1804th position and lysine at the 1966th position in the amino acid sequence of the polyprotein of hepatitis C virus.Type: ApplicationFiled: July 15, 2009Publication date: November 24, 2011Inventors: Noboru Maki, Kenichi Mori, Hiromi Fukai
-
Publication number: 20110283945Abstract: An isolated nucleic acid molecule comprising, or consisting of, a polynucleotide sequence encoding an oligopeptide capable of inducing post-mating depression of receptivity to mating in female insects, wherein said oligopeptide is resistant to proteolytic degradation, is provided for expression in sterile transgenic male insects useful in the control of insect populations.Type: ApplicationFiled: July 30, 2008Publication date: November 24, 2011Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Shalom Applebaum, Yael Heifetz
-
Publication number: 20110283373Abstract: A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the C-terminal portion of the thermostable luciferase to the N-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase. The linker contains a sensor region capable of interacting with a target molecule in a cell. The modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the parental circularly-permuted thermostable luciferase in the presence of the target molecule. Alternatively, the modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the modified circularly-permuted thermostable luciferase in the absence of the target molecule.Type: ApplicationFiled: May 11, 2011Publication date: November 17, 2011Inventors: Brock BINKOWSKI, Braeden BUTLER, Lance P. ENCELL, Frank FAN, Brad HOOK, Paul OTTO, Gediminas VIDUGIRIS, Susan WIGDAL, Kristopher ZIMMERMAN
-
Publication number: 20110277043Abstract: The present invention relates to polynucleotides from Cochliobolus heterostrophus C5, Cyanothece sp. CCY0110, Mycocentrospora acerina and Hyaloperonospora parasitica, which code for desaturases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides according to the invention, and to the polypeptides encoded by the polynucleotides. The invention furthermore relates to antibodies against the polypeptides according to the invention. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions and to their use as drugs, cosmetics, foodstuffs, feedstuffs, preferably fish food, or food supplements.Type: ApplicationFiled: December 8, 2009Publication date: November 10, 2011Applicant: BASF Plant Science Company GmbHInventors: Toralf Senger, Jörg Bauer, Johnathan A. Napier
-
Publication number: 20110277044Abstract: The present invention relates to isolated polypeptides having esterase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: January 15, 2010Publication date: November 10, 2011Applicant: Novozymes A/SInventors: Dan Pettersson, Wenping Wu, Lan Tang, Ye Liu
-
Publication number: 20110271358Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.Type: ApplicationFiled: September 25, 2009Publication date: November 3, 2011Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
-
Publication number: 20110271357Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: October 25, 2010Publication date: November 3, 2011Applicant: CELERA CORPORATIONInventors: Yeounjin KIM, Tao HE, Steve RUBEN
-
Publication number: 20110265192Abstract: A sensor system for detecting the activation of specific nuclear receptors in a tissue of an animal is provided. The nuclear receptor sensor system comprises a sensor component comprising a nuclear receptor or part thereof coupled to a DNA-binding domain, and a reporter component comprising a reporter gene. Transgenic animals, such as a transgenic pig is provided, which comprises the components of the nuclear receptor sensor system in its genome. Also methods of producing the transgenic animal is provided as well as use of the transgenic animal for evaluating the activity of a nuclear receptor in vivo.Type: ApplicationFiled: September 3, 2009Publication date: October 27, 2011Applicants: SYDDANSK UNIVERSITET, AARHUS UNIVERSITETInventors: Lars Axel Bolund, Karsten Kristiansen, Jacob Giehm Mikkelsen, Nicklas Heine Staunstrup